GRI Bio Inc. (GRI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GRI Bio Inc. (GRI) has a cash flow conversion efficiency ratio of -0.495x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.97 Million) by net assets ($6.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check GRI Bio Inc. strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
GRI Bio Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how GRI Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. See GRI net asset value for net asset value and shareholders' equity analysis.
GRI Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GRI Bio Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Scisparc Ltd
NASDAQ:SPRC
|
22.975x |
|
Marelius Inc.
NASDAQ:MBPG
|
1.216x |
|
VCI Global Limited Ordinary Share
NASDAQ:VCIG
|
0.154x |
|
Decoy Therapeutics Inc.
NASDAQ:DCOY
|
-0.745x |
|
James Fisher and Sons PLC
LSE:FSJ
|
0.150x |
|
Abrdn UK Smaller Companies Growth Trust PLC
LSE:AUSC
|
0.012x |
|
Scout Gaming Group AB
ST:SCOUT
|
-0.665x |
|
Alakasa Industrindo Tbk
JK:ALKA
|
0.034x |
Annual Cash Flow Conversion Efficiency for GRI Bio Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of GRI Bio Inc. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see how much is GRI Bio Inc. worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.01 Million | $-10.19 Million | -1.695x | +20.61% |
| 2024-12-31 | $4.03 Million | $-8.61 Million | -2.136x | +93.85% |
| 2023-12-31 | $259.00K | $-8.99 Million | -34.710x | -5298.57% |
| 2022-12-31 | $-1.62 Million | $-1.08 Million | 0.668x | +272.39% |
| 2021-12-31 | $-4.72 Million | $-847.00K | 0.179x | -92.97% |
| 2020-12-31 | $-1.45 Million | $-3.71 Million | 2.549x | +384.06% |
| 2019-12-31 | $3.21 Million | $-2.88 Million | -0.897x | +94.21% |
| 2018-12-31 | $152.94K | $-2.37 Million | -15.503x | -- |
About GRI Bio Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung … Read more